C-Corp Blockers for Tax-Sensitive SPV Investors

A C-corp blocker SPV is the industry label for a corporate entity placed between a tax-sensitive investor and a partnership vehicle so that partnership items hit a corporation first. Tax-exempts worried about UBTI, and some foreign investors worried about ECI or filing obligations, are the usual audiences for the conversation. This page is educational only. It is not tax advice, not a structuring recommendation, and not an offer to form a blocker for any LP.

Allocations administers SPVs and funds; it does not design tax blockers or give tax opinions. Confirm any structure with counsel and a tax advisor.

What "blocker" means in an SPV stack

In venture and private-markets jargon, a blocker is usually a C corporation (state-law corporation, or an LLC that has elected association under Form 8832) that:

1. Owns the partnership interest (or the assets) that would otherwise sit in the LP's hands, and

2. Is taxable as a corporation for U.S. federal income tax, so flow-through character does not land directly on the sensitive investor.

Contrast with the default deal SPV: a multi-member Delaware LLC that defaults to partnership classification and issues Schedule K-1s (SPV EIN and tax classification; check-the-box Form 8832). Partnership items of income, gain, loss, and deduction flow to partners. That pass-through is exactly what some LPs want -- and exactly what others want to avoid.

A blocker is not:

• A synonym for "Premium SPV."

• A guarantee that UBTI, ECI, or FIRPTA exposure disappears.

• Free. Corporate tax, entity maintenance, and possible double tax on exit are real costs someone pays.

This article lists why the topic arises. It does not say your syndicate should insert a blocker, where it should sit, or which jurisdiction to use.

Why tax-exempt and IRA investors raise the topic

Tax-exempt organizations and IRAs are subject to tax on unrelated business taxable income (UBTI / UBIT). IRS Publication 598 and the UBTI discussion for IRA holders of SPV interests are covered in UBTI when an IRA holds an SPV interest and Can an IRA invest in an SPV.

In plain terms, an IRA or 501(‌c) partner that receives an allocation of operating or debt-financed income from a partnership may have a Form 990-T problem even when the "same" economic exposure held as C-corp stock would produce dividends or capital gain that Pub. 598 generally excludes. Some investors therefore prefer to hold corporate stock (or an interest in a corporate feeder) rather than a direct partnership interest in the deal SPV.

That preference is an investor-side tax preference. It is not a GP marketing claim that "our SPV never creates UBTI." GPs should not promise UBTI outcomes. GPs should point IRA and exempt LPs to their advisors and custodians, report K-1 boxes accurately, and avoid debt-financed surprises at the vehicle.

Debt-financed income under IRC Section 514 and look-through to lower-tier partnerships remain facts questions. A blocker does not erase bad facts above or below it; it changes which person is the corporate taxpayer on the blocked slice.

Why foreign investors raise the topic

Foreign partners in a U.S. partnership can face:

• Filing obligations tied to effectively connected income,

• Withholding under IRC Section 1446(a) on ECTI allocable to foreign partners,

• Withholding under Section 1446(f) on transfers of partnership interests, and

• FIRPTA (Section 1445) when USRPIs are in play.

High-level withholding context sits in FIRPTA and non-US investor withholding in an SPV and investor onboarding forms in W-9 vs W-8BEN for SPV investors. Some foreign LPs prefer corporate blockers so that partnership ECI character and K-1 complexity sit behind a corporate return. Others use treaty planning, W-8ECI, or simply avoid the deal. Listing those options is not a recommendation.

Corporate blockers introduce their own issues: entity-level U.S. corporate tax, possible branch-profits or withholding on distributions, and state tax. "Blocker" is not a synonym for "no U.S. tax."

Where blockers sit (map, not blueprint)

GPs hear three common topologies in market conversation. Naming them is descriptive:

None of these rows is an Allocations product SKU. Allocations' published vehicles are formation and administration of Delaware LLCs / funds with partnership defaults unless counsel files elections. Published cash fees fetched 4 Sep 2026 from fees: Standard SPV $9,950 one-time; Premium SPV $19,500 one-time; Fund $19,500/year. Additional fees may apply. Platform carry is 0%. Those prices are administration, not blocker design fees.

If an LP arrives with its own blocker already formed, onboarding looks like any other corporate subscriber: W-9 or W-8BEN-E as applicable, KYC on the corporate entity, and K-1s (or corporate reporting) per the classification the IRS applies to that entity. See Form 1065 and SPV K-1s for the partnership layer.

Costs and tradeoffs investors actually model

Educational checklist only -- not a recommendation to build or skip a blocker:

1. Entity-level corporate tax on income and gains trapped in the C corp, versus pass-through character on a K-1.

2. Second level of tax when the corporation distributes or when the investor exits stock, depending on facts and holding period.

3. Setup and maintenance -- formation, board formalities, separate return, and possibly a separate bank account and EIN.

4. Cap-table clarity -- the deal SPV sees one corporate member; the sensitive humans sit behind that member's own docs.

5. Withholding and forms -- corporate subscribers still need correct W-9 / W-8 packages; foreign corporate blockers do not erase chapter 3 / 4 analysis.

IRA custodians may refuse some partnership interests or require representations about UBTI. That is a custodian policy issue, covered in the IRA and UBTI insights linked above, not a reason for a GP to improvise tax law on a call.

If the sensitive capital is large enough that blocker friction is on the table, the GP's job is narrower: keep the deal SPV's classification, OA, and fee schedule clean; let the LP's counsel own the blocker. Mixing GP promote design with LP tax architecture in one Slack thread is how closings slip.

What GPs should say -- and should not say

Say:

• The deal SPV is a partnership by default unless Form 8832 or corporate formation says otherwise.

• Tax-sensitive LPs should talk to their own advisors about blockers, IRA custodians, and UBTI.

• Allocations will administer the vehicle you form; classification elections are advisor-led.

• Cash admin fees and 0% platform carry are on fees and SPV.

Do not say:

• "Subscribe through our blocker and you will have no UBTI."

• "Foreign LPs never need W-8s if we use a C corp."

• "Platform carry funds your tax structure."

• Anything that sounds like Allocations is giving a tax opinion.

For emerging managers comparing vehicle choice rather than blocker topology, use emerging managers, fund, and banking. Economics of promote vs vendor fees sit in platform carry vs GP carry and carried interest explained.

Does every tax-exempt LP need a C-corp blocker SPV?

No. Many tax-exempt and IRA investors hold partnership interests directly and monitor UBTI with their advisors. A blocker is one tool some investors use; it is not mandatory and not universally efficient.

Does a blocker eliminate FIRPTA?

Not necessarily. USRPI facts can still create FIRPTA or related withholding depending on what is disposed of and by whom. See the FIRPTA insight; do not treat a corporate label as a FIRPTA waiver.

Can the deal SPV itself be the blocker?

A deal vehicle can be a corporation (or an LLC electing association), but that changes tax results for all members, not only the sensitive ones. Most U.S. venture syndicates stay default partnership at the deal layer. Ask counsel; do not elect from a blog.

Will Allocations recommend a blocker structure?

No. Allocations provides formation and administration. Blocker design is a counsel and tax-advisor project. Published fees cover administration SKUs, not tax opinions.

Is this tax advice?

No. This is general educational information. It is not a recommendation to form, use, or avoid a C-corp blocker. Confirm every structure with qualified advisors.